CelLBxHealth plc (ANPCF) Stock Price & Analysis
CelLBxHealth plc (ANPCF) — price $0.0098 (0.00%), as of the Nov 18, 2026 trading session; market cap $11.1M.
Educational signal · not a buy or sell recommendation · How to read this
CelLBxHealth plc · ANPCF
CelLBxHealth plc, formerly ANGLE plc, is a UK-based medical diagnostic company specializing in cancer diagnostics. It develops Parsortix systems for capturing circulating tumor cells (CTCs) from patient blood, along with related kits and laboratory services, operating globally.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0098 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0098 – $0.025 | |
| Market capitalisation | $11.1M | |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for CelLBxHealth (ANPCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is CelLBxHealth (ANPCF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CelLBxHealth plc (ANPCF) is the company analyzed here. It employs 119 people and is led by Peter Michael Collins. In Q2 FY2026 it reported revenue of £592,774 and net income of -£3M. The market values it at $11.1M.
What do the latest results show for CelLBxHealth (ANPCF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of £592,774.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | £592,774 | -£3M | -£0.0024 (diluted) |
| Q1 FY2026 | £298,500 | -£1M | -£0.0012 (diluted) |
| Q4 FY2025 | £554,910 | -£10M | -£0.01 (diluted) |
| Q3 FY2025 | £277,500 | -£5M | -£0.01 (diluted) |
What are the financial strengths and risks for CelLBxHealth (ANPCF)?
Short answer · as of
The distress and quality screens read Altman Z -32.54 · Piotroski F 2. Trailing ratios: ROA -37.2% · current ratio 2.54.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -32.54 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ANPCF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ANPCF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about CelLBxHealth (ANPCF)?
Common Questions About ANPCF
These answers are editorial: 1 of these 1 answer is drawn from the ANPCF research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
How does Cellbxhealth PLC's Parsortix system differentiate itself in the liquid biopsy market?
CelLBxHealth PLC's Parsortix system differentiates itself significantly in the liquid biopsy market through its unique ability to capture intact circulating tumor cells (CTCs).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com